logo-loader
viewOptiBiotix Health PLC

OptiBiotix unveils human study showing probiotic “can reduce high blood pressure”

Statistically significant reductions were shown in both systolic and diastolic blood pressure levels as well as cholesterol levels, which was consistent with a UK study in 2017

OptiBiotix Health PLC -

OptiBiotix Health PLC (LON:OPTI) said a human study for a new food supplement containing its LPLDL probiotic has shown it “can reduce high blood pressure”.

The AIM-listed company’s ProBiotix and Italy’s Nutrilinea carried out a three-month study of 40 patients by the Center of Diabetes and Metabolic Diseases at the University of Pavia and Fondazione IRCCS Policlinico San Matteo in Italy.

Statistically significant reductions were shown in both systolic and diastolic blood pressure levels as well as cholesterol levels, which was consistent with a UK study in 2017.

ProBiotix and Nutrilinea agreed on the study last May, with the Italian company funding the development, manufacture and human studies for a new blood pressure product in return for 12 months exclusivity for the European market, which began on 18 December.

ProBiotix retains exclusivity for the UK and all markets outside Europe.

“Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension,” said ProBiotix chief executive Steve Prescott.

“Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome and CholBiome x3, allows ProBiotix to offer a best in class cardiovascular health solutions to consumers.”

Quick facts: OptiBiotix Health PLC

Price: 30.5 GBX

AIM:OPTI
Market: AIM
Market Cap: £26.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health CEO discusses recent big deals and its focus on profitability

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara caught up with Proactive London's Andrew Scott after announcing they've signed a one-year deal with Lebanon-based Prosperous Pharma - a pharmaceutical distributor that also supplies nutraceuticals to doctors, pharmacies and consumers. It will...

1 week, 4 days ago

2 min read